Skip to main content

Table 2 Isolated cardiomyocyte contractile measurements

From: Adverse transverse-tubule remodeling in a rat model of heart failure is attenuated with low-dose triiodothyronine treatment

 ShamMI + VehMI + T3
Maximum Shortening Velocity (μm/s)3.513 ± 0.8083.125 ± 0.7263.703 ± 1.213
Maximum Relengthening Velocity (μm/s)2.299 ± 0.8371.593 ± 0.3252.984 ± 1.410#
Time at Maximum Relengthening Velocity (s)0.248 ± 0.0480.314 ± 0.019*0.233 ± 0.037#
Peak Height as Percent of Baseline11.17 ± 1.9711.70 ± 1.6812.11 ± 2.96
Time at % from Baseline to Peak Shortening (s)    
50%0.049 ± 0.0060.053 ± 0.0050.054 ± 0.009
90%0.109 ± 0.0140.130 ± 0.0060.105 ± 0.020#
Time at Peak Shortening (s)0.165 ± 0.0240.197 ± 0.011*0.161 ± 0.021#
Time at % from Peak Shortening to Full Relengthening (s)    
50%0.258 ± 0.0500.326 ± 0.018*0.261 ± 0.071#
90%0.353 ± 0.0710.443 ± 0.024*0.324 ± 0.071#
Tau (exponential decay time constant) (s)0.048 ± 0.0190.067 ± 0.0080.045 ± 0.021#
Area Under Curve of Relengthening Phase0.021 ± 0.0060.029 ± 0.004*0.020 ± 0.005#
  1. Values are mean ± SD. MI, myocardial infarction; Veh, vehicle; T3, triiodothyronine. Tau is exponential decay time constant of the sarcomere relengthening phase. Sham, n = 7; MI + Veh, n = 8, MI + T3, n = 8. One-way ANOVA, multiple group comparisons using Tukey’s analysis. *p < 0.05 vs Sham, #p < 0.05 vs MI + Veh